PTC Therapeutics Stock Income Statements

PTC Therapeutics Quarterly Income Statements Chart

Quarterly

Annual

Operating Profit

PTC Therapeutics Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30

revenues:
net product revenue	118,329,000	153,426,000	154,706,000	135,421,000	133,220,000	177,604,000	155,062,000	144,038,000	174,592,000	187,557,000	127,508,000	134,186,000	143,701,000	129,832,000	118,906,000	115,605,000	103,113,000	91,280,000	107,258,000	82,708,000	75,239,000	68,196,000	81,407,000	71,369,000	85,476,000	53,054,000	85,833,000	53,021,000	68,170,000	55,981,000	57,953,000	41,780,000	47,891,000	26,442,000	25,119,000	22,013,000	15,437,000	18,878,000	9,772,000	6,161,000	5,069,000
collaboration and license revenue	2,941,000	986,231,000
royalty revenue	57,605,000	36,439,000	58,162,000	61,365,000	53,183,000	31,154,000	50,999,000	50,173,000	36,853,000	30,831,000	39,876,000	32,924,000	21,825,000	18,896,000	21,295,000	13,127,000	13,563,000	6,655,000	174,000	696,000
manufacturing revenue					301,000	1,360,000	971,000	2,365,000	2,363,000	1,988,000
total revenues	178,875,000	1,176,096,000	213,172,000	196,786,000	186,704,000	210,118,000	307,056,000	196,576,000	213,808,000	220,382,000	167,412,000	217,127,000	165,526,000	148,735,000	165,229,000	138,743,000	116,676,000	117,942,000	118,864,000	118,404,000	75,239,000	68,259,000	96,459,000	71,416,000	85,522,000	53,583,000	86,338,000	53,591,000	68,743,000	56,062,000	78,030,000	41,853,000	47,962,000	26,547,000	25,191,000	22,986,000	15,633,000	18,895,000	9,776,000	6,774,000	7,482,000	1,694,000	1,677,000	9,217,000
operating expenses:
cost of product, collaboration and license sales, excluding amortization of acquired intangible assets	11,420,000	12,862,000
amortization of acquired intangible assets	4,061,000	3,798,000	3,307,000	3,036,000	2,865,000	51,530,000	77,174,000	58,649,000	47,397,000	39,415,000	35,764,000	31,023,000	26,294,000	23,473,000	16,340,000	14,383,000	12,751,000	11,278,000	10,583,000	9,630,000	8,731,000	7,949,000	4,919,250	7,025,000	6,575,000
research and development	112,990,000	108,973,000	124,770,000	161,412,000	132,169,000	116,129,000	121,353,000	164,212,000	185,874,000	195,124,000	188,694,000	165,462,000	157,263,000	140,078,000	149,844,000	130,845,000	125,482,000	134,513,000	118,013,000	92,998,000	176,525,000	90,107,000	81,831,000	63,076,000	59,979,000	52,566,000	53,647,000	54,368,000	32,607,000	31,363,000	29,234,000	30,024,000	30,835,000	27,363,000	26,011,000	31,396,000	28,827,000	31,399,000	30,640,000	28,190,000	27,938,000	18,765,000	18,313,000	15,889,000	13,886,196	14,712,091
selling, general and administrative	85,262,000	80,961,000	84,683,000	73,456,000	69,500,000	73,272,000	76,291,000	80,886,000	88,449,000	86,914,000	92,718,000	80,118,000	79,892,000	73,271,000	86,548,000	69,252,000	68,878,000	61,095,000	75,456,000	57,840,000	53,659,000	58,209,000	63,497,000	49,284,000	49,215,000	40,544,000	48,666,000	38,368,000	33,545,000	32,969,000	35,483,000	31,423,000	28,866,000	25,500,000	24,172,000	23,654,000	23,366,000	25,938,000	21,368,000	17,210,000	17,615,000
change in the fair value of contingent consideration		-800,000	-10,175,000	700,000	5,100,000	-100,000	-2,700,000	1,500,000	-128,900,000
tangible asset impairment and losses (gains) on transactions	99,000		-2,855,000	1,844,000	1,761,000
total operating expenses	213,832,000	205,871,000	375,561,000	251,296,000	226,922,000	255,571,000	301,236,000	314,740,000	423,351,000	337,997,000	367,753,000	285,314,000	257,888,000	235,257,000	249,959,000	231,819,000	215,169,000	216,090,000	215,238,000	173,535,000	262,512,000	161,250,000	169,243,000	131,891,000	124,280,000	122,723,000	131,476,000	101,821,000	74,317,000	72,805,000	72,580,000	72,745,000	60,459,000	52,902,000	50,183,000	55,050,000	52,193,000	57,337,000	52,008,000	45,400,000	45,553,000	29,295,000	27,046,000	23,429,000	20,565,188	21,307,148
income from operations	-34,957,000	970,225,000	-162,389,000	-54,510,000	-40,218,000	-45,453,000	5,820,000	-118,164,000	-209,543,000	-117,615,000	-200,341,000	-68,187,000	-92,362,000	-86,522,000	-84,730,000	-93,076,000	-98,493,000	-98,148,000	-96,374,000	-55,131,000	-187,273,000	-92,991,000	-72,784,000	-60,475,000	-38,758,000	-69,140,000	-45,138,000	-48,230,000	-5,574,000	-16,743,000	5,450,000	-30,892,000	-12,497,000	-26,355,000	-24,992,000	-32,064,000
yoy	-13.08%	-2234.57%	-2890.19%	-53.87%	-80.81%	-61.35%	-102.91%	73.29%	126.87%	35.94%	136.45%	-26.74%	-6.22%	-11.85%	-12.08%	68.83%	-47.41%	5.55%	32.41%	-8.84%	383.19%	34.50%	61.25%	25.39%	595.34%	312.95%	-928.22%	56.12%	-55.40%	-36.47%	-121.81%	-3.66%
qoq	-103.60%	-697.47%	197.91%	35.54%	-11.52%	-880.98%	-104.93%	-43.61%	78.16%	-41.29%	193.81%	-26.17%	6.75%	2.11%	-8.97%	-5.50%	0.35%	1.84%	74.81%	-70.56%	101.39%	27.76%	20.35%	56.03%	-43.94%	53.17%	-6.41%	765.27%	-66.71%	-407.21%	-117.64%	147.20%	-52.58%	5.45%	-22.06%
operating margin %
interest expense	-30,358,000	-34,092,000	-41,060,000	-41,609,000	-43,490,000	-40,834,000	-44,275,000	-28,160,000	-29,415,000	-27,331,000	-24,500,000	-20,880,000	-21,976,000	-23,514,000	-22,502,000	-21,802,000	-22,559,000	-19,159,000	-24,292,000	-21,039,000	-5,379,000	-5,642,000	-5,463,000	-2,666,000	-2,074,000	-2,288,000	-3,248,000	-3,118,000	-2,884,000	-3,303,000	-3,446,000	-3,421,000	-3,008,000	-2,219,000
other income	-5,737,000	-6,305,000	8,850,000	-1,872,000	-2,025,000	1,591,000	18,962,000	-20,266,000	1,479,000	9,956,000	35,148,000	-38,141,000	-34,357,000	-11,855,000	-31,376,000	-18,782,000	3,170,000	-10,884,000	58,946,000	28,766,000	11,309,000	-13,832,000	11,214,000	2,800,000	-183,000	-109,000	-937,000	734,000	-673,000	1,004,000	94,000	766,000	-1,820,000	-318,000	686,000	-786,000							17,000
income before income tax benefit	-71,052,000		-94,699,000	-97,991,000	-85,733,000		-157,051,000	-166,590,000	-237,479,000
income tax benefit	6,203,000		28,813,000	-8,663,000	-13,446,000		1,259,000	33,620,000	38,596,000		18,804,000	17,893,000			-226,000	36,000			-12,634,000	-22,288,000			-10,644,000	344,000									-150,000				93,000
net income attributable to common stockholders	-64,849,000	866,562,000	-65,886,000	-106,654,000	-99,179,000	-91,576,000	-155,792,000	-132,970,000	-198,883,000	-138,959,000	-170,889,000	-109,315,000	-152,087,000	-126,726,000	-143,265,000	-133,624,000	-118,370,000	-128,642,000	-74,354,000	-69,692,000	-181,427,000	-112,687,000	-77,677,000	-59,997,000	-41,789,000	-72,113,000	-48,330,000	-50,969,000	-9,520,000	-19,263,000	1,270,000	-33,738,000	-17,475,000	-29,057,000	-26,796,000	-35,167,000	-38,914,000	-41,233,000				-27,282,000	-25,104,000	-14,098,000	-4,416,499	-14,586,578
weighted-average shares outstanding:
basic	78,151,240,000	78,115,836,000																																											23,803,282	2,648,832
diluted	78,151,240,000	86,385,922,000
net income per share	-0.83	11.09	-0.85	-1.39	-1.29	-1.2	-2.06	-1.76	-2.66	-1.88	-2.36	-1.53	-2.13	-1.78	-2.02	-1.89	-1.68	-1.83	-1.05	-1.03	-2.78	-1.81	-1.26	-1.06	-0.75	-1.29	-0.99	-1.06	-0.21	-0.46	0.07	-0.82	-0.44	-0.85	-0.78	-1.03	-1.14	-1.22	-1.27	-1.14	-1.15	-0.93	-0.86	-0.58	-0.19	-5.51
tangible asset impairment and losses on transactions		77,000
income before income tax expense		929,828,000				-84,696,000				-134,990,000	-189,693,000	-127,208,000	-148,695,000	-121,891,000	-138,608,000	-133,660,000	-117,882,000	-128,191,000	-61,720,000	-47,404,000	-181,343,000	-112,465,000	-67,033,000	-60,341,000	-41,015,000	-71,537,000	-49,323,000	-50,614,000	-9,131,000	-19,042,000	2,098,000	-33,547,000	-17,325,000	-28,892,000	-28,777,000	-34,983,000
income tax expense		-63,266,000				-6,880,000				-3,969,000			-3,392,000	-4,835,000			-488,000	-451,000			-84,000	-222,000			-774,000	-576,000	-241,000	-355,000	-389,000	-221,000	-828,000	-191,000		-165,000	-51,500	-184,000
collaboration revenue							100,024,000			6,000	28,000	50,017,000		7,000	25,028,000	10,011,000		20,007,000																					2,000	207,000	338,000	716,000	1,418,000	9,147,000	15,455,361	5,867,806
cost of product sales, excluding amortization of acquired intangible assets			16,283,000	10,848,000	15,527,000	14,740,000	29,118,000	9,493,000	12,731,000	14,144,000	10,893,000	14,011,000	9,639,000	10,135,000	9,327,000	6,539,000	7,358,000	9,104,000	4,886,000	4,667,000	5,304,000	4,085,000	2,148,250	3,006,000	3,211,000
intangible asset impairment									217,800,000
weighted-average shares outstanding:
basic and diluted			76,845,055,000	76,925,523,000	76,725,070,000	76,496,127,000	74,838,392,000	75,377,997,000	74,730,433,000	73,729,284,000	71,728,634,000	71,654,671,000	71,372,940,000	71,215,105,000	70,466,393,000	70,585,938,000	70,414,632,000	70,188,602,000	66,027,908,000	67,641,171,000	65,150,780,000	62,389,158,000	58,863,185,000	56,463,528,000	55,912,748,000	55,855,111,000	46,576,313,000	48,096,521,000	46,137,833,000	41,626,617,000	39,183,073,000	41,296,740,000	39,621,738,000	34,305,948,000	34,044,584,000	34,088,741,000	34,000,333,000	33,919,169,000	33,908,853,000	33,600,653,000	33,067,752,000	29,351,693,000	29,332,227,000	24,492,487,000
change in the fair value of deferred and contingent consideration										2,400,000	6,300,000	-5,300,000	-15,200,000	-11,700,000	-12,100,000	10,800,000	700,000	100,000	6,300,000	8,400,000	7,680,000	900,000	12,400,000	9,500,000	5,300,000	21,160,000
settlement of deferred and contingent consideration																			2,653,250		10,613,000
collaboration and grant revenue																			8,765,750	35,000,000		63,000	15,052,000	47,000	46,000	529,000	505,000	570,000	573,000	81,000	20,077,000	73,000	71,000	105,000	72,000	973,000	196,000	17,000
cost of product sales, excluding amortization of acquired intangible asset																										2,376,000	3,761,000	3,292,000	2,572,000	3,045,000	2,435,000	1,582,000
amortization of acquired intangible asset																										6,077,000	6,062,000	5,793,000	5,593,000	5,428,000	5,428,000	9,716,000
cost of product sales																																	758,000	39,000
interest income																																			-2,127,000	-2,133,000				498,000	524,000	354,000	248,000	171,000	26,695
grant revenue																																							2,000	406,000	2,075,000	897,000	259,000	70,000	834,212	986,406
interest (expense)/income
net income																																							-43,223,000	-38,361,000	-37,915,000
yoy
qoq																																							12.67%	1.18%
net income margin %
other (expense)/income
net product sales																																										81,000
general and administrative																																										10,530,000	8,733,000	7,540,000	6,678,992	6,595,057
loss on extinguishment of debt
deemed dividend
gain on exchange of convertible preferred stock in connection with recapitalization
total revenues and non-cash cancellation revenue																																													16,289,573	6,854,212
less beneficial conversion charge
weighted-average shares outstanding:
basic	78,151,240,000	78,115,836,000																																											23,803,282	2,648,832
diluted																																													23,803,282	2,648,832

We provide you with 20 years income statements for PTC Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PTC Therapeutics stock. Explore the full financial landscape of PTC Therapeutics stock with our expertly curated income statements.

The information provided in this report about PTC Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.